Neo Ivy Capital Management Takes $598,000 Position in Edwards Lifesciences Corporation $EW

Neo Ivy Capital Management acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,684 shares of the medical research company’s stock, valued at approximately $598,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. True Wealth Design LLC raised its holdings in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares during the period. Rakuten Securities Inc. raised its stake in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in Edwards Lifesciences in the third quarter worth approximately $30,000. Finally, Strengthening Families & Communities LLC purchased a new stake in Edwards Lifesciences during the third quarter worth $34,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Trading Down 2.6%

Edwards Lifesciences stock opened at $81.71 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The stock has a market cap of $47.46 billion, a PE ratio of 44.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.93. The stock has a 50-day moving average of $82.56 and a two-hundred day moving average of $81.47. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of a number of analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Piper Sandler reissued an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. BTIG Research reaffirmed a “buy” rating and issued a $103.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Finally, Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 12th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,827,387.38. This represents a 34.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 79,144 shares of company stock valued at $6,685,688. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.